Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,845 | N/A | 7,181 | N/A | 13,250 |
| Other current assets | 496 | 0 | 817 | 0 | 565 |
| TOTAL | $4,341 | $N/A | $7,997 | $N/A | $13,815 |
| Non-Current Assets | |||||
| Intangibles | 14 | 0 | 16 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 17 |
| TOTAL | $14 | $N/A | $16 | $N/A | $17 |
| Total Assets | $4,355 | $N/A | $8,013 | $N/A | $13,832 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,671 | 0 | 1,031 | 0 | 947 |
| Accrued Expenses | 1,566 | N/A | 2,402 | N/A | 3,148 |
| Other current liabilities | 1,347 | N/A | 1,705 | N/A | 7,946 |
| TOTAL | $4,584 | $N/A | $5,137 | $N/A | $12,041 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 94 | 0 | 0 |
| TOTAL | $N/A | $N/A | $94 | $N/A | $N/A |
| Total Liabilities | $4,584 | $N/A | $5,232 | $N/A | $12,041 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | N/A | N/A | N/A | 3,722 |
| Common Shares | 1,324 | N/A | 1,012 | N/A | 745 |
| Retained earnings | -227,461 | N/A | -220,452 | N/A | -217,453 |
| Other shareholders' equity | 51,154 | 0 | 51,368 | 0 | 51,423 |
| TOTAL | $-229 | $N/A | $2,782 | $N/A | $1,791 |
| Total Liabilities And Equity | $4,355 | $0 | $8,013 | $0 | $13,832 |